DCPH News and Press, Deciphera Pharmaceuticals Inc. From 05/02/22

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,501,239 shares of ...

Deciphera Pharmaceuticals (NASDAQ:DCPH) priced its underwritten public offering of 5.25M shares at $10/share. The company is also offering 9.75M shares at a purchase price of $9.99/pre-funded warrant. Underwriters granted 30-day option to purchase up to an additional 2.25M shares. Procee...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 5,251,239 shares of i...

Deciphera Pharmaceuticals (NASDAQ:DCPH) on Tuesday said it intends to offer and sell $150M of shares and pre-funded warrants to buy shares of its common stock in an underwritten public offering. DCPH stock -5.4% to $9.80 in aftermarket trade. Deciphera also intends to grant the underwriters a...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it intends to offer and sell $150,000,000 of shares of its common ...

– ULK Inhibitor DCC-3116 Shown to Inhibit KRAS G12C Inhibitor-induced Autophagy in Mutant KRAS G12C NSCLC Cell Lines – – DCC-3116 in Combination with KRAS G12C Inhibitors Translated to Deeper and Longer Tumor Regressions than KRAS G12C Inhi...

Gainers: Aeglea BioTherapeutics (AGLE) +10%. Gossamer Bio (GOSS) +8%. Resources Connection (RGP) +7%. Conn's (CONN) +6%. Pixelworks (PXLW) +5%. Losers: Qorvo (QRVO) -7%. SoFi Technologies (SOFI) -5%. Deciphera Pharmaceuticals (DCPH) -5%. Oxford Lane Capital  (OXL...

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) traded today at a new 52-week high of $70.84. Approximately 26.2 million shares have changed hands today, as compared to an average 30-day volume of 1.2 million shares. Deciphera Pharmaceuticals Inc is a biotechnology company, which develops a...

Deciphera's ripretinib failed a critical trial. The stock has been decimated. Although the company is struggling to make a comeback, it will take time. For further details see: Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now